Bonjour, new guests from small-town India
Puneet Dhawan of Accor is brimming with ideas on ways to revive the hospitality sector
ICICI Securities
Sun Pharmaceutical Ind (Buy)
CMP: ₹392.6
Target: ₹478
Sun Pharmaceutical Industries Ltd is a pharmaceuticals company. The company’s business segments include US business, Indian branded generics business, emerging markets, global consumer healthcare business and active pharmaceutical ingredients (API). Its rest-of-the-world segment includes Western Europe, Canada, Australia, New Zealand and other markets. The company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs.
Sun Pharmaceutical Industries’ stock price has corrected about 20 per cent in the past two months and we believe the key concerns of slow ramp-up of specialty portfolio and likely negative outcome in ensuing US DOJ (Department of Justice) case for generic drug price fixing have been factored in the current valuations.
Resolution of generic drug price fixing case by Sandoz with US DOJ indicates a possible resolution by Sun Pharma (including Taro) which could be positive in our view as it would remove a major overhang from the stock. The company continues to focus on cost rationalisation measures and improving its product mix. Strong performance in India business and stability in base business margin despite slow ramp-up in specialty portfolio are likely to continue.
Upgrade to ‘buy’ with revised target price of ₹478/share (earlier ₹445/share).
Key downside risks are: Regulatory hurdles and adverse outcome on generic price fixing case with US DOJ with significant penalty.
Puneet Dhawan of Accor is brimming with ideas on ways to revive the hospitality sector
Citroen’s first vehicle sports a novel design and European interiors. It is also meant to be as comfortable as ...
The pandemic is only the tip of the iceberg that the country’s cash-poor airlines — both regional and national ...
The government is yet to specify the framework of its recently announced old vehicle scrappage policy
With initial public offerings galore, we give you a cheat sheet to score some good grades
Biggest risk in selling funds in a rising scenario is exiting early and missing out on further gains
Go for a standard vector-borne diseases policy if you don’t have a regular health plan
No credit risk is an attraction, but note the nuances
After facing severe droughts for several years, farmers in western Maharashtra have turned the corner through ...
A toast to a traditional drip irrigation system still going strong in the Northeast
Raza Mir’s ‘Murder at the Mushaira’ works well as a historical novel that captures the sunset years of the ...
If you see garbage lying on the streets, remove it, says a dedicated plogger on a clean-up drive
Its name is the starting point of a brand’s journey and can make a big difference in the success sweepstakes
Sober spirits are the in thing
A peek into where ad spends went last year and where they are headed tomorrow
Can Swiggy Instamart disrupt the ecommerce groceries space, currently ruled by the Amazons and Big Baskets? ...
Three years after its inception, compliance with GST procedures remains a headache for exporters, job workers ...
Corporate social responsibility (CSR) initiatives of companies are altering the prospects for wooden toys of ...
Aequs Aerospace to create space for large-scale manufacture of toys at Koppal
And it has every reason to smile. Covid-19 has triggered a consumer shift towards branded products as ...
Please Email the Editor